ViiV Healthcare, Drug Prices & Medicare Spending
ViiV Healthcare manufactures 6 drugs tracked by Medicare Part D with total spending of $4.8B.
ViiV Healthcare Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Triumeq | Dolutegravir/Abacavir/Lamivudine | $3,580.00 | Yes |
| 2 | Dovato | Dolutegravir/Lamivudine | $2,910.00 | Yes |
| 3 | Juluca | Dolutegravir/Rilpivirine | $3,831.00 | Yes |
| 4 | Cabenuva | Cabotegravir/Rilpivirine | $6,593.00 | Yes |
| 5 | Tivicay | Dolutegravir | $2,452.00 | Yes |
| 6 | Rukobia | Fostemsavir | $6,833.00 | Yes |
Frequently Asked Questions
ViiV Healthcare manufactures 6 drugs tracked by Medicare Part D, with total annual spending of $4.8B.
Rukobia (Fostemsavir) is the most expensive at $6,833.00 per claim.
6 of 6 ViiV Healthcare drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Source: CMS Medicare Part D Spending, 2026.